Author
Listed:
- Zehava Grossman
- Jonathan M Schapiro
- Itzchak Levy
- Daniel Elbirt
- Michal Chowers
- Klaris Riesenberg
- Karen Olstein-Pops
- Eduardo Shahar
- Valery Istomin
- Ilan Asher
- Bat-Sheva Gottessman
- Yonat Shemer
- Hila Elinav
- Gamal Hassoun
- Shira Rosenberg
- Diana Averbuch
- Keren Machleb-Guri
- Zipi Kra-Oz
- Sara Radian-Sade
- Hagit Rudich
- Daniela Ram
- Shlomo Maayan
- Nancy Agmon-Levin
- Zev Sthoeger
Abstract
Background: Analysis of potentially different impact of Lopinavir/Ritonavir (LPV/r) on non-B subtypes is confounded by dissimilarities in the conditions existing in different countries. We retrospectively compared its impact on populations infected with subtypes B and C in Israel, where patients infected with different subtypes receive the same treatment. Methods: Clinical and demographic data were reported by physicians. Resistance was tested after treatment failure. Statistical analyses were conducted using SPSS. Results: 607 LPV/r treated patients (365 male) were included. 139 had HIV subtype B, 391 C, and 77 other subtypes. At study end 429 (71%) were receiving LPV/r. No significant differences in PI treatment history and in median viral-load (VL) at treatment initiation and termination existed between subtypes. MSM discontinued LPV/r more often than others even when the virologic outcome was good (p = 0.001). VL was below detection level in 81% of patients for whom LPV/r was first PI and in 67% when it was second (P = 0.001). Median VL decrease from baseline was 1.9±0.1 logs and was not significantly associated with subtype. Median CD4 increase was: 162 and 92cells/µl, respectively, for patients receiving LPV/r as first and second PI (P = 0.001), and 175 and 98, respectively, for subtypes B and C (P
Suggested Citation
Zehava Grossman & Jonathan M Schapiro & Itzchak Levy & Daniel Elbirt & Michal Chowers & Klaris Riesenberg & Karen Olstein-Pops & Eduardo Shahar & Valery Istomin & Ilan Asher & Bat-Sheva Gottessman & Y, 2014.
"Comparable Long-Term Efficacy of Lopinavir/Ritonavir and Similar Drug-Resistance Profiles in Different HIV-1 Subtypes,"
PLOS ONE, Public Library of Science, vol. 9(1), pages 1-14, January.
Handle:
RePEc:plo:pone00:0086239
DOI: 10.1371/journal.pone.0086239
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pone00:0086239. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosone (email available below). General contact details of provider: https://journals.plos.org/plosone/ .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.